Navigation Links
Actavis Launches Oxymorphone Hydrochloride Extended-Release Tablets, CII in the U.S.
Date:7/20/2011

MORRISTOWN, N.J., July 20, 2011 /PRNewswire/ -- Actavis, an international generic pharmaceutical company, today announced that it has begun shipping Oxymorphone Hydrochloride Extended-Release Tablets, CII 7.5mg and 15mg, a generic equivalent of Opana ER®.

The 7.5mg and 15mg strength of Opana ER had U.S. total sales of approximately $21.9 million for the 12 months ending March 31, 2011, according to IMS Health.  

Commenting on the launch, Michael Perfetto, Vice President, Sales & Marketing of Actavis, Inc. in the United States said:

"Oxymorphone Extended-Release Tablets offer significant value to our customers and patients.  This launch exemplifies Actavis' focus, commitment and capability in bringing complex controlled-release products to our customers."

Please see prescribing information at www.actavis.us/oxymorphone.

About Actavis:

Actavis Inc. is the U.S. distributor of the product and the U.S. subsidiary of Actavis Group hf.  Approximately one third of Actavis Group hf's sales are generated in North America, Actavis' single largest market. Based in Morristown, NJ, Actavis Inc. has U.S. manufacturing facilities in Elizabeth, NJ and Lincolnton, NC. Actavis also has research and development facilities in Elizabeth, NJ, Owings Mills, MD and Sunrise, FL.

Actavis Group hf is one of the world's leading generic pharmaceutical companies specializing in the development, manufacture and sale of generic pharmaceuticals.  The company has operations in 40 countries, with more than 10,500 employees.

Opana ER ® is a trademark owned by a party other than Actavis.

Information in this press release may contain forward-looking statements with respect to the financial condition, results of operations and businesses of Actavis.  By their nature, forward-looking statements and forecasts involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future. There are a number of factors that could cause actual results and developments to differ materially from that expressed or implied by these forward-looking statements. These factors include, among other things, exchange rate fluctuations, the risk that research and development will not yield new products that achieve commercial success, the impact of competition, price controls and price reductions, the risk of loss or expiration of patents or trade marks, difficulties of obtaining and maintaining governmental approvals for products, the risk of substantial product liability claims, exposure to environmental liability.


'/>"/>
SOURCE Actavis Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Actavis Hails U.S. Supreme Court Decision in Labeling Cases
2. Actavis Receives FDA Approval of Zolpidem Tartrate Extended-Release Tablets USP, 12.5 mg CIV in the U.S.
3. Actavis Receives FDA Approval of Donepezil Hydrochloride Tablets in the U.S.
4. Actavis Receives Approval of Valacyclovir Hydrochloride Tablets in the U.S.
5. Actavis Receives Approval of Pantoprazole Sodium Delayed-Release Tablets, USP in the U.S.
6. Actavis Encourages Consumers to Return Fentanyl Transdermal System 25 mcg/h
7. Actavis Inc. Issues a Voluntary Recall of 18 Lots of Fentanyl Transdermal System 25 mcg/h
8. Actavis Receives Approval of Zolpidem Tartrate Extended-Release Tablets, USP 6.25mg CIV in the U.S. with 180-Day Marketing Exclusivity
9. Actavis Receives Approval of Losartan Potassium Tablets, USP in the U.S.
10. Actavis Receives FDA Approval of Atomoxetine HCl Capsules
11. Actavis Receives Approval of Bupropion HCl SR 100mg and 200mg in the U.S.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/19/2016)... 19, 2016  Global Blood Therapeutics, Inc. (GBT) (NASDAQ: ... for the treatment of grievous blood-based disorders with significant ... be presented in a poster session at the European ... Copenhagen . The presentations will include additional ... sickle cell disease (SCD), including 90-day data from a ...
(Date:5/19/2016)... , May 19, 2016  IBM,s (NYSE:   IBM )  ... study to identify drug candidates to cure Zika, a ... declared a global public health emergency. IBM ... with a computer or Android device to join the ... or money to help; they simply  run an app ...
(Date:5/18/2016)... 19, 2016 Global ... Report initially provides a basic overview of ... manufacturing technology, post which the report explores ... the market. Complete report on ... providing 8 company profiles and 98 tables ...
Breaking Medicine Technology:
(Date:5/23/2016)... Angeles, CA (PRWEB) , ... May 23, 2016 ... ... to connecting doctors and patients to provide information about cosmetic procedures, began updating ... now started to rewrite each of their published articles in order to feature ...
(Date:5/23/2016)... , ... May 23, 2016 ... ... security executive networking and relationship-marketing firm, announced today that nominations will be ... Security Executive® (ISE®) Northeast Awards. , Awards include the Information Security Executive® ...
(Date:5/23/2016)... ... May 23, 2016 , ... ... residents of Westchester County for over 24 years, recently hosted its sixth annual ... joined HOW for two remembrance ceremonies, each concluding with the release of Monarch ...
(Date:5/23/2016)... ... May 23, 2016 , ... Overweight and obesity in children can ... the budget, but most of all, it can be hard on the child carrying ... diet food—isn’t making a dint in childhood obesity statistics or making it easier for ...
(Date:5/23/2016)... ... May 23, 2016 , ... A team of cardiovascular surgeons ... the first in the region to use a groundbreaking new technology to provide ... Program partnered with AHN to introduce the technology to the Pittsburgh market. , ...
Breaking Medicine News(10 mins):